Patient preferences in treatment of erectile dysfunction: The continuing importance of patient education

Clinical Cornerstone

Volumn 7, Issue 1, 2005, Pages 57-64

  Hackett, Geoff I ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL; CARBOLINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SULFONE; TRIAZINE DERIVATIVE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEALTH CARE NEED; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PENIS ERECTION; PENIS PROSTHESIS; PHYSICIAN; PUMP; SEXUAL BEHAVIOR; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; VACUUM; IMPOTENCE; MALE; PATIENT SATISFACTION; REVIEW; SAFETY;

CARBOLINES; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PATIENT EDUCATION; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SAFETY; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 27744545923     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(05)80049-3     Document Type: Article

References (28)

1. Jarow JP Burnett AL Geringer AM Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment J Urol 162 1999 722-725
2. Hellstrom WJ Gittelman M Karlin G Segerson T Thibonnier M Taylor T et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Urology 61 4 Suppl 1 2003 8-14
3. Madduri SD After two years, did Viagra live up to its expectations? Mo Med 98 2001 243-245
4. Finelli A Hirshberg ED Radomski SB The treatment choice of elderly patients with erectile dysfunction Geriatr Nephrol Urol 8 1998 15-19
5. Nusbaum MR Therapeutic options for patients returning to sexual activity J Am Osteopath Assoc 104 3 Suppl 4 2004 S2-S5
6. Hanson-Divers C Jackson SE Lue TF Crawford SY Rosen RC Health outcomes variables important to patients in the treatment of erectile dysfunction J Urol 159 1998 1541-1547
7. Braun M Wassmer G Klotz T Reifenrath B Mathers M Englemann U Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey' Int J Impot Res 12 2000 305-311
8. Marwick C Survey says patients expect little physician help on sex JAMA 281 1999 2173-2174
9. Solstad K Hertoft P Frequency of sexual problems and sexual dysfunction in middle-aged Danish men Arch Sex Behav 22 1993 51-58
10. Shabsigh R Perelman MA Laumann EO Lockhart DC Drivers and barriers to seeking treatment for erectile dysfunction: A comparison of six countries BJU Int 94 2004 1055-1065
11. Giuliano F Montorsi F Mirone V Rossi D Sweeney M Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study. The Sildenafil Multicenter Study Group J Urol 164 2000 708-711
12. Chen J Mabjeesh NJ Greenstein A Sildenafil versus the vacuum erection device: Patient preference J Urol 166 2001 1779-1781
13. Hatzichristou DG Apostolidis A Tzortzis V Ioannides E Yannakoyorgos K Kalinderis A Sildenafil versus injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year J Urol 164 2000 1197-1200
14. Ströberg P Murphy A Costigan T Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference Clin Ther 25 2003 2724-2737
15. Taylor H Leitman R editors. Men with erectile dysfunction (ED) want improved relations with their partners. Health Care News Harris Interactive 1(14) 2001
16. Ichikawa T Takao A Manabe D Saegusa M Tanimoto R Aramaki K et al. The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction Int J Urol 11 2004 755-762
17. Rajpurkar A Dhabuwala CB Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice J Urol 170 2003 159-163
18. Kim SC Chang IH Jeon HJ Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year BJU Int 92 2003 277-280
19. Eardley I Wright P MacDonagh R Hole J Edwards A An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction BJU Int 93 2004 1271-1275
20. Rosen RC Fisher WA Eardley I Niederberger C Nadel A Sand M The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population Curr Med Res Opin 20 2004 607-617
21. Carson C Hatzichristou D Carrier S Lording D Young J Murdoch M Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: Results of a phase III clinical trial. PROVEN: Patient Response with Vardenafil in Sildenafil Non-responders Presented at the 5th Annual Research Meeting of the Sexual Medicine Society of North America 2003 Oct 11; Denver CO, USA Available from: http://www.smsna.org/meetings/October2OO3Slideshow/ Sat101-103balIroomA/PROVENSMSNACarson files/v3_document.html.
22. Carson C Murdoch M Aliotta P Hatzichristou D Auerbach S Carrier S et al. Vardenafil significantly improves erectile function in diabetics who are sildenafil nonresponders: PROVEN trial results Presented at the 64th Annual Scientific Sessions of the American Diabetes Association (ADA) 2004 Jun 4-8 Orlando (FL), USA.
23. Levitra® (vardenafil HCI) prescribing information 2004 Bayer Pharmaceuticals Corporation West Haven, (CT)
24. von Keitz A Rajfer J Segal S Murphy A Denne J Costigan T et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil Eur Urol 45 2004 499-507
25. Eardley I Editorial Comment on Eur Urol 45 2004 507-508
26. Montorsi F Editorial Comment on Eur Urol 45 2004 508-509
27. Govier F Potempa AJ Kaufman J Denne J Kovalenko P Ahuja S A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction Clin Ther 25 2003 2709-2723
28. Araujo AB Mohr BA McKinlay JB Changes in sexual function in middle-aged and older men: Longitudinal data from the Massachusetts Male Aging Study J Am Geriatr Soc 52 2004 1502-1509